Healthy Clinical Trial
Official title:
Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination
Verified date | April 2010 |
Source | Vakzine Projekt Management GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Paul-Ehrlich-Institut |
Study type | Interventional |
Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against TB for residents in endemic areas and persons at risk in non-endemic areas. The new live vaccine VPM1002 should be at least as potent as the currently used BCG vaccine and should cause fewer side effects (Kaufmann, 2007; Grode et al., 2005). It is formulated as lyophilised bacteria to be resuspended before intradermal injection. First application of VPM1002 in human male volunteers will evaluate its safety, local and systemic tolerability as well as its immunogenicity. The study has a dose-escalating sequential design with comparison to commercially available BCG. 80 volunteers in Germany will randomly be allocated to 4 groups each with 20 volunteers stratified for their history of BCG-vaccination.
Status | Completed |
Enrollment | 80 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Male volunteers 18 to 55 years of age. 2. Healthy (medical history, physical examination, vital signs, ECG and laboratory tests at screening). 3. No signs of active or latent tuberculosis infection. 4. BMI of 19 - 30 kg/m2. 5. Subjects must be able and willing to comply with the study protocol, available and willing to complete all study measurements and have signed an Informed Consent form approved by the Ethics Committee. 6. Intention not to travel to endemic regions for tuberculosis (such as Africa, Asia, former USSR) and reachable by phone during the whole study period (6 months). 7. Negative test for HIV1 and HIV2, hepatitis B surface antigen and antibody to hepatitis C virus . 8. No anamnestic evidence for a primary or secondary immunodeficiency. 9. No skin eczema lesion at the intended injection site. 10. No anamnestic predisposition for scarring badly or for keloid formation. 11. No other vaccination during eight weeks before and during the follow-up period of the current study. If a vaccination is necessary during this period, the volunteer will be withdrawn from the study. 12. No participation in another clinical trial within 3 months before study vaccination and the 6 months of the current study. 13. Able and willing to abstain from physical exercise 24 hours before screening examination, and from 24 hours before admission until discharge from the clinic. 14. No blood donation for non study-related purposes during the entire duration of the study. 15. normal sonographic liver imaging Exclusion Criteria: For the group of volunteers who were vaccinated with a BCG vaccine: • Tuberculin-PPD-in-vivo-test equal or more than 10 mm at baseline For the group of naive volunteers: • Tuberculin-PPD-in-vivo-Test equal or more than 1 mm at baseline For all volunteers 1. systemic disorders which could interfere with the interpretation of the study results or compromise the health of the volunteers. 2. BCG-vaccination during 10 years before study vaccination. 3. Acute fever or fever in the last 7 days before dosing. 4. Any malignant condition. 5. Concomitant treatment with medication that may affect immune function during 3 months before study vaccination and the 6 months of current study. 6. Treatment with blood products or Immunoglobulins in the past 6 months up to end of study. 7. Any clinically significant laboratory abnormalities on screened blood samples. 8. A history of drug or alcohol abuse. 9. History of anaphylaxis or severe allergic reactions. 10. Positive test for drugs of abuse on urine testing at screening or admission. 11. Known allergies to any component of the investigational or reference product or known history of severe skin reaction against the Tuberculin test. 12. Professional or regular contact with life animals for food production. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Germany | Focus Clinical Drug Development GmbH | Neuss |
Lead Sponsor | Collaborator |
---|---|
Vakzine Projekt Management GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety: physical examination, vital signs, ECG, liver sonography, chest X-ray, laboratory safety parameters (including haematology, coagulation, clinical chemistry and urinalysis), tolerability, recording of concomitant medication and adverse events | days -1, 1, 2, 3, 5, 11, 29, 57 and month 6 | Yes | |
Secondary | Immunogenicity: LST for PPD with subsequent IFN-gamma specific ELISA on supernatants of PBMC | baseline, days 29, 57, month 6 | No | |
Secondary | Immunogenicity: ELISPOT for the number of IFN-gamma secreting PBMC after stimulation with PPD | baseline, days 29, 57, month 6 | No | |
Secondary | Immunogenicity: whole blood stimulated with PPD and measuring IFN-gamma in the plasma by ELISA | baseline, days 29, 57, month 6 | No | |
Secondary | ICS for IFN-gamma, TNF-alpha and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation with PPD | baseline, days 29, 57 and month 6 | No | |
Secondary | Immunogenicity: ICS with other triple combinations of markers in CD4+ and CD8+ lymphocytes upon stimulation with PPD | baseline, days 29, 57 and month 6 | No | |
Secondary | Immunogenicity: TB85B as recall antigen for ELISA, ELISPOT, WBA and ICS | baseline, days 29, 57 and month 6 | No | |
Secondary | Immunogenicity: serum antibodies against PPD or AG85B | baseline, days 29, 57 and month 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |